Indian Scientists Map Venom Gland of Social Spider, Identify Molecules for Future Drug Research
NEW DELHI: A team of Indian researchers has produced the first comprehensive molecular and functional profile of the venom gland of Stegodyphus sarasinorum, a colonial spider species found across the Indian subcontinent. The study, published in the peer-reviewed journal Scientific Reports, identifies numerous proteins and small molecules that could serve as promising leads for future drug discovery, particularly in the areas of cancer and antimicrobial research.
The research was led by A.P. Ajay Kumar of the Department of Zoology at Sree Neelakanta Government Sanskrit College, Pattambi, with experimental work carried out by research scholar Veena Venugopal. Collaborators from Calicut University, S.N. College Nattika, St. Joseph's College Devagiri, PSG Institute of Advanced Studies Coimbatore, GITAM University Andhra Pradesh, and Ajman University in the UAE also contributed to the study.
Unlike most spiders that live solitary lives, Stegodyphus sarasinorum builds permanent communal silk nests and hunts prey cooperatively. It is one of the few known permanently social spider species in the world, making it a valuable model for studying both spider behaviour and venom biology. While spider venoms have long drawn scientific interest due to their diverse biological activities, this is the first study to comprehensively analyse the molecular composition of the venom gland of this species.
The team used an integrated multi-omics approach, combining transcriptomics, proteomics, metabolomics and Confocal Raman Spectroscopy to examine the venom gland in detail. Transcriptomic profiling identified 31 protein components, while proteomic analysis detected 32 proteins. Ultra High-Performance Liquid Chromatography-Mass Spectrometry (UHPLC-MS) revealed 81 metabolites, including amino acids, biogenic amines and organic acids, providing a detailed molecular inventory of the venom gland.
To investigate the biological activity of these molecules, the researchers tested venom gland extracts against Dalton's Lymphoma Ascites (DLA) cancer cells in laboratory experiments. The extracts showed dose-dependent cytotoxicity, meaning that higher concentrations destroyed a greater proportion of cancer cells. While this suggests the venom gland contains molecules with anti-cancer potential, the experiments were conducted only on cultured cells.
Among the most significant findings were several protein families already known for their biomedical relevance. These include hemocyanin proteins, which are known to stimulate immune responses and have drawn interest in cancer immunotherapy research. The study also detected U12 and U20 lycotoxins, peptide molecules that can disrupt the membranes of bacteria and cancer cells, making them promising templates for the future development of antimicrobial and targeted anti-cancer compounds.
The researchers caution that these findings represent an early stage of biomedical research. Extensive validation is required before any clinical application becomes possible. Further studies involving additional cancer models, healthy cells, animal testing and eventually clinical trials will be necessary to determine whether any of these molecules can be developed into therapeutic agents.
The study opens a new avenue for exploring the biomedical potential of social spider venom, but the path from laboratory discovery to medicine is long and uncertain. The scientific community will watch closely as follow-up research unfolds.
